Navigation Links
New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes,Using Self-Adjusted Dosing Starting With Once-Daily Insulin,Treatment Levemir

ta showed that patient self-adjustment of insulin treatment with Levemir® was as safe and effective when compared to dosing that was adjusted by physicians according to standard-of-care. The patients who self-adjusted their dosage achieved a level of diabetes control that was comparable to that of patients receiving physician-driven adjustments. Minimal weight change was observed in both trial arms.1

The findings on weight gain are consistent with previous studies of Levemir®, the first insulin to show less weight gain versus other basal insulins in 12 of 12 controlled clinical trials*. Weight gain is a common side effect of insulin therapy, which is a concern given that 80 percent of people with type 2 diabetes are overweight or obese.

About the Study (Abstract #197-OR):
The new data presented at ADA were from a six-month analysis of 5,604 Type 2 diabetes patients, in a mainly primary care settings, and predominantly treated with Levemir® once-daily, as an add-on therapy to any other glucose-lowering regimens, or as replacement of a previous basal insulin. Patients were randomized to either the “303 Algorithm” [self adjusting their Levemir® dose every three days based on fasting plasma glucose (FPG)] or “Standard-of-Care” (Levemir® dose was physician-adjusted according to standard-of-care) treatment groups.
The study showed that the average A1c, an indicator of long-term blood glucose control, decreased from 8.5 percent at baseline to 7.9 percent at 26 weeks for the 303 Algorithm group, and from 8.5 percent to 8.0 for Standard-of-Care group (p=0.001). Compared to baseline, FPG values decreased by 34 and 21 mg/dL for 303 Algorithm and Standard-of-Care groups, respectively (p<0.0001).
At 26 weeks, 88 percent of all patients remained on once-daily Levemir® therapy. In a subset of insulin-naïve patients who added Levemir® to their standard-of-care therapy, well ove
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- Inc. ... for the third straight year, No. 349 in ... exclusive ranking of the nation,s fastest-growing private companies. ... the most important segment of the economy—America,s independent ... Domino,s Pizza, LinkedIn, Zillow, and many other well-known ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ScriptPro has ... (HITRUST) under its Common Security Framework (CSF). According ... and Privacy Manager, "We appreciate this rigorous, top-to-bottom ... commitment that this certification signifies. Our business partners ... ABOUT THE CSF CERTIFICATION PROCESS: ScriptPro,s internal security ...
(Date:8/21/2014)... Aug. 21, 2014  Zacks.com announces the list of stocks ... Research analysts discuss the latest news and events impacting stocks ... include the Hewlett-Packard (NYSE: HPQ - Free Report ), IBM ... (NYSE: SB - Free Report ), GlaxoSmithKline plc (NYSE: ... (NYSE: FI - Free Report ). Today, ...
Breaking Medicine Technology:Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3ScriptPro Achieves HITRUST Certification 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
... 14 Spherix Incorporated,(Nasdaq: SPEX ) reported ... potential,type 2 diabetes drug, Naturlose(R), will expand outside ... of treatment-naive type II,diabetics are being considered. "This ... the first quarter of 2009, which is consistent ...
... a Safe and Effective ... Diabetes Patients, PHILADELPHIA, July 14 GlaxoSmithKline ... Drug Administration (FDA),updated the prescribing information for AVANDIA(R) ... Outcome Progression Trial,(ADOPT), a 4- to- 6 year ...
Cached Medicine Technology:Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S. 2FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 2FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years 3
(Date:8/22/2014)... August 22, 2014 AWeber, one ... that currently helps more than 120,000 small businesses ... the attention of Shane Michaels, prompting an investigative review. ... element for any online marketing campaign, despite what some ... the marketing world,” reports Michaels. “AWeber is a great ...
(Date:8/22/2014)... MyWriters.com , an online source for ... for marketers to help them drive traffic to their ... Shane Michaels, prompting an investigative review. , “Anyone ... knows that content is king when it comes to ... even though content is extremely important, creating quality, original ...
(Date:8/22/2014)... This report studies the "Sample Preparation Market by ... Kits (Isolation, Purification), By Application (Genomics, Proteomics), by ... 2018" This market was valued at $4,254.8 million ... a CAGR of 5.9% from 2013 to 2018, ... 98 market data Tables and 23 Figures spread ...
(Date:8/22/2014)... Boston, Mass. (PRWEB) August 22, 2014 ... Chain Drug Stores (NACDS) Total Store Expo - which ... Boston Globe published a pro-pharmacy op-ed in its online ... medical care, enlist pharmacists ” is co-authored by Steven ... and Michael Malloy, PharmD, dean of the MCPHS University ...
(Date:8/22/2014)... Millennium Treatment Group has recently noticed an increase ... of drug use among teenagers. The treatment facility aims to ... work to minimize drug abuse. , America is currently seeing ... in history. According to the National Institute of Drug ... 12 or older—or 9.2 percent of the population—had used an ...
Breaking Medicine News(10 mins):Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 3Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2
... passed on a rare side effect of the smallpox vaccination he ... , The boy who is currently being treated at University of ... percent of his body. ,Eczema vaccinatum is an unusual ... receive the shot or their close contacts. , The ...
... journal Proceedings of the National Academy of Sciences. The report ... in// preventing tuberculosis, and scientists may do well to resurrect ... led by Dr. Roland Brosch of the Institut Pasteur ... vaccines used in immunization of 2 million children around ...
... the first in the state to perform a novel ... regeneration of the heart muscle after a// heart attack. ... in the country providing this new treatment modality as ... a privately funded cell-therapy company studying stem cells for ...
... gene variants in Hispanic women are linked to spontaneous preterm ... Washington University.// ,The research was presented at the ... 16. ,Preterm birth is a major cause of ... birth was suggested by racial disparity, a tendency to occur ...
... have developed a procedure that estimates the reproductive potential ... multiple births and to achieve a higher success rate ... fertilization procedures are performed each year in the United ... in IVF cycles, but only 34.3 percent resulted in ...
... part of the body, could be an indicator of common ... development of new treatment. ,Zinc had previously been ... brains of patients with Alzheimer's disease. It is also vital ... ,Zinc is particularly important for healthy skin and ...
Cached Medicine News:Health News:Toddler Infected With Rare Side Effect of Smallpox Vaccine 2Health News:TB Vaccines: Ring Out the New, Bring in the Old 2Health News:Vanderbilt Performs State's First Stem Cell Heart Regeneration Therapy 2Health News:Vanderbilt Performs State's First Stem Cell Heart Regeneration Therapy 3Health News:Gene Variants Linked to Preterm Birth in Hispanic Women 2
... Our one-of-kind Expander ... solve the problem of ... fit. The Expander Sizer™ ... perfect solution to post ...
For lipoplasty of trochanteric area, abdomen, thighs, hips, buttocks and flanks...
Black Spandex Above the Knee Compression Girdles with Contact Closure with Zipper...
Short Girdle, High Waist, Mid-thigh...
Medicine Products: